Position in ALKS
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$4,407,415
+$1,433,993 QoQ
Shares Held
84,111
+0.0% QoQ
Ownership
0.050%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#128
of 421 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALKS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Vident Advisory, LLC holds $34,283,611 across 24 Drug Manufacturers - Specialty & Generic names. ALKS ranks #2 (12.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VTRS |
Viatris Inc
|
317,141 | $5,036,196 | |
| 2 | ALKS |
Alkermes plc.
This page
|
84,111 | $4,407,415 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
6,535 | $3,540,857 | |
| 4 | RDY |
Dr Reddys Laboratories Ltd
|
187,312 | $2,714,150 | |
| 5 | ZTS |
Zoetis Inc.
|
33,892 | $2,435,477 | |
| 6 | TAK |
Takeda Pharmaceutical Co Ltd
|
143,921 | $2,307,052 | |
| 7 | NBIX |
Neurocrine Biosciences Inc
|
13,348 | $2,249,670 | |
| 8 | HLN |
Haleon plc
|
214,226 | $1,998,728 |
All Filings in ALKS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,407,415 | 84,111 | Shares | Defined | 2026-08-12 | |
| 2026-03-31 | $2,973,422 | 84,090 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $2,302,585 | 82,294 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $2,442,900 | 81,430 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $1,704,469 | 59,576 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $1,876,097 | 56,817 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $1,901,927 | 66,131 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $1,928,062 | 68,884 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||